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Abstract
Cholestasis is defined as the impairment in formation or excretion of bile from 
the liver to the intestine. It may result from defects in intrahepatic production of 
bile, impairment of hepatic transmembrane transporters, or mechanical obstruc-
tion to bile flow. In cholestasis, hepatocytes are exposed to high levels of bile acids, 
particularly those bearing hydrophobic properties. The increase in bile acids 
induces oxidative stress, leading to an imbalance in the prooxidant:antioxidant ratio 
which determines the final cellular redox status. This chapter will focus on the close 
relationship between bile acids and the most powerful endogenous antioxidant, 
coenzyme Q10 in cholestasis, and the eventual alternative therapeutic option of 
CoQ10 supplementation to current traditional therapies.
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1.  Cholestasis: types, clinical presentation, diagnosis and current 
therapeutic approaches
Bile is a nonenzymatic secretion produced by hepatocytes. The main compo-
nents of bile include bile salts necessary for enzymatic fat digestion and absorption, 
bilirubin, and cholesterol. Drugs and other xenobiotics are also excreted into bile 
following hepatic metabolization. Bile flow is dependent on the active canalicular 
transport of bile acids and other substrates mediated by the bile salt export pump 
(Bsep), which transports osmotically active monoanionic bile salts into the bile 
canaliculus and multidrug resistance-associated protein 2 (Mrp2), which exports 
oxidized and reduced glutathione. Bile secreted by the hepatocytes is stored and 
concentrated in the gallbladder, which contracts in the presence of the hormone 
cholecystokinin resulting in bile release into the duodenum through the cystic and 
common bile duct.
Cholestasis is defined as the decrease or suppression of bile flow due to impaired 
secretion by hepatocytes or to obstruction of bile at any level of the excretory 
pathway, from the hepatocyte canalicular membrane to the ampulla of Vater in 
the duodenum. Cholestasis leads to the retention of the major constituents of bile, 
bilirubin, and bile acids, in blood. By convention, cholestasis is chronic when it 
lasts more than 6 months. Prevalence of cholestasis is not significantly different 
between males and females. Nevertheless, women are at lighter risk of developing 
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drug-induced cholestasis and intrahepatic cholestasis of pregnancy. Despite that, 
cholestasis may affect people of every age group, newborns and infants are more 
prone due to the immaturity of the liver.
The morphologic features of cholestasis are dependent on the severity, duration, 
and the underlying cause. Cholestasis is classified as intrahepatic or extrahepatic 
cholestasis depending on the cause that leads to impaired bile flow. Intrahepatic 
cholestasis is due to a disease affecting the hepatocytes and/or the intrahepatic bile 
ducts, whereas extrahepatic cholestasis or obstructive cholestasis results from the 
obstruction of the extrahepatic biliary ducts.
Obstruction of bile ducts can be caused by gallstones, cysts, stenosis, or tumors. 
The most frequent causes of extrahepatic cholestasis in adults include cholelithiasis 
and malignancies of the biliary tree or the head of the pancreas. However, in chil-
dren, biliary atresia and cystic fibrosis are the main causes. Intermittent or partial 
obstruction may lead to ascending cholangitis, a secondary bacterial infection of 
the biliary tree. The typical morphological changes are reversible if the obstruction 
is corrected, but if it persists it can lead to biliary cirrhosis.
Causes of intrahepatic or hepatocellular cholestasis include viral and autoim-
mune hepatitis, inborn errors of bile acid synthesis, primary biliary cirrhosis, 
progressive familial intrahepatic cholestasis, primary sclerosing cholangitis, 
total parenteral nutrition, and drug toxicity. The drug class mostly implicated in 
cholestasis is antibiotics. However, anti-inflammatory drugs, highly active antiret-
roviral therapy, psychotropes, some chemotherapy agents, oral contraceptives, and 
anabolic steroids have also been reported to cause cholestasis [1]. Although primary 
sclerosing cholangitis affects intrahepatic bile ducts, it can also affect extrahepatic 
bile ducts.
Clinical presentation of cholestasis includes jaundice, pruritus, skin xanthomas, 
or symptoms associated with intestinal malabsorption. Jaundice and pruritus are 
present in all types of cholestasis whether acute or chronic, whereas the other clini-
cal features are more associated with chronic cholestasis.
Jaundice is the clinical expression of bilirubin retention. Excretion of conjugated 
bilirubin is the rate-limiting step of bilirubin clearance. During cholestasis, con-
jugation of bilirubin continues but the excretion is significantly reduced. Jaundice 
is observed by scleral icterus at a concentration as low as 2 mg/dL accompanied 
by dark urine. The concentration of conjugated bilirubin in blood depends on its 
production rate and excretion pathways, as well as cholestasis degree. Non con-
jugated bilirubin is also increased in patients with cholestasis. The magnitude of 
the increase in serum bilirubin concentration does not correlated with the type or 
severity of cholestasis. Pruritus is a frequent clinical manifestation of cholestasis, 
which has been long associated with increased serum bile acids. However, its origin 
is multifactorial and diverse studies show that not only bile acids but also lysophos-
phatidic acid, and bilirubin are potential mediators of cholestatic itch [2]. Retention 
of bile acids and their conjugated salts results in biological membrane injury, 
particularly in the liver due to their detergent properties. Increased hydrophobic 
bile salts favor their incorporation into membranes, altering membrane fluidity 
and function. Enhanced secondary bile acids like lithocholic acid result in further 
membrane injury. The transport of bile salts from plasma to bile is the principal 
driving force for bile formation and it is mediated by several hepatic transporters, 
mostly belonging to the ABC family of transporters. Numerous studies support that 
the failure to excrete bile salts into the canaliculus is the main mechanism underly-
ing cholestasis. In this sense retrieval of the canalicular transporters Bsep and Mrp2 
from hepatocyte plasma membrane to endosomal compartments in different types 
of cholestasis has been well documented [3, 4]. However, other works consider that 
the endocytic retrieval of canalicular transporter is the result of cholestasis on the 
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hepatocyte function. In either case, the retention of bile salts in the liver induces 
down-regulation of bile acid synthesis, overall reduction in the total pool size and 
damage to hepatocytes.
Skin xanthomas and signs of malabsorption are associated with chronic cho-
lestasis. Skin xanthomas result from focal accumulation of cholesterol in the dermis 
and usually appear around the eyes, but may be present in other parts of the body. 
Malabsorption occurs due to the failure of enough bile salts to reach the duodenum, 
so the digestion and absorption of dietary fat is impaired. Fat soluble vitamins like 
A, E, D, and K are poorly absorbed in cholestasis leading to clinical symptoms and 
signs of their deficiency.
In all types of cholestasis, characteristic laboratory findings are elevated 
serum alkaline phosphatase and γ-glutamyltranspeptidase, enzymes present on 
the canalicular membranes of hepatocytes, and bile duct epithelial cells. Alkaline 
phosphatase is also elevated in bone growth or disease, pregnancy, or intestinal 
diseases. λ-Glutamyltranspeptidase is a sensitive marker of cholestasis [5], although 
no specific since it can be elevated in other liver diseases [6]. Furthermore, its eleva-
tion may reflect enzyme induction by drugs or alcohol. Serum 5′-nucleotidase, an 
enzyme located in canalicular membranes and lining the sinusoids is also elevated 
in cholestasis, although it appears to be less sensitive than alkaline phosphatase. 
Serum elevation of hepatic enzymes is accompanied by increased serum bilirubin 
and bile acids. An increase in serum bile acids is an early marker of cholestasis.
In the diagnosis of cholestasis, the first key step is to identify whether it is 
intrahepatic, extrahepatic, or both. The patient history and physical examination 
usually provide useful information. Elevation of both hepatic enzymes (alkaline 
phosphatase and λ-glutamyl transpeptidase) is a hallmark of cholestasis although 
the identification of the type of cholestasis requires imaging studies and additional 
biochemical studies. Imaging studies include first an abdominal ultrasonography 
to exclude dilated intra and extrahepatic ducts. When bile duct alterations are 
observed, further imaging studies like magnetic resonance cholangiopancreatog-
raphy or endoscopic retrograde cholangiopancreatography should be performed. 
A diagnostic of intrahepatic cholestasis can be made when imaging studies exclude 
mechanical obstruction. Then, further biochemical studies are necessary to identify 
the intrahepatic cause of cholestasis, including liver biopsies when the diagnosis is 
unclear.
The therapeutic intervention for cholestasis may differ depending on the etiol-
ogy [7]. Based on controlled clinical trials, ursodeoxycholic acid (UDCA) is the 
treatment of choice for diverse cholestatic disorders like primary biliary cirrhosis 
and intrahepatic cholestasis of pregnancy due to its anticholestatic properties. 
However, UDCA treatment is not so effective in other cholestatic disorders like 
in primary sclerosing cholangitis. No therapy of proven benefit for the long-term 
prognosis of genetic cholestatic liver disease exists. In drug-induced cholestasis, 
withdrawal of the drug is the only effective treatment [8]. Pruritus is a common 
manifestation of cholestasis, which can be of serious severity. Management of 
pruritus includes cholestyramine as first line-treatment and then rifampicin, and 
opiate antagonists [9].
2. Bile acids: physicochemical properties, synthesis, and therapeutics
2.1 Bile acids physicochemical properties
Bile acids (BA) are steroid compounds, hydroxyl derivatives of 5β-cholan-24 
oic acid. Primary BA are cholic acid (CA) and chenodeoxycholic acid (CDCA); 
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secondary BA such as deoxycholic acid (DCA) and lithocholic acid (LCA), all of 
them in 3α-position, and ursodeoxycholic acid (UDCA) is a hydroxyl derivative in 
3β-position (Figure 1) [10].
BA have different physicochemical properties according to the number, posi-
tion, and orientation of their hydroxy groups and the conjugation with glycine 
and taurine (Figure 1). In this sense, this characteristic influence their solubility, 
detergency, and hydrophobicity [11].
BA have an important role in biological systems under physiological and 
pathological conditions [12]. Their functions are associated with lipid digestion 
and absorption, solubilization of cholesterol and bile formation. In this case, BA 
influence in volume and composition of the bile.
The number, position, and orientation of the hydroxy groups of the BA impact 
directly on the hydrophobicity and detergency property and the relationship to 
the toxicity. In the case of BA with hydroxy groups in 3-α position, the higher the 
number of hydroxy groups, less hydrophobicity and lower detergency and, as a 
result, lower toxicity.
It must be pointed out that the orientation of the hydroxy group rules over the 
properties in the molecule. This can be seen on the CDCA (7α) and its epimer, 
the UDCA (7β), where the UDCA showed a strong reduction of detergency and 
hydrophobicity. Also, the BA toxicity is directly related to its hydrophobicity 
and detergency, because those interact with the cellular membranes in different 
ways, including the union, the insertion in the lipidic bilayer and its solubilization 
increasing its fluidity [10].
Therefore, UDCA is administered as therapeutic agent for the treatment of 
hepatobiliary disorders such as cholestasis, biliary dyspepsia, primary biliary cir-
rhosis, and different cholestatic conditions.
2.2 Bile acids synthesis
The synthesis of BA is produced exclusively in the liver, based on a series of 
enzymatic reactions in the hepatocyte, in which 17 enzymes are involved. The 
cholesterol (hydrophobic compound) turns into the primary BA, also known as 
colic acid (CA) and chenodeoxycholic (CDCA), through the first step and limiting 
of the called “classic” or “neutral” way of the BA biosynthesis, where the hydrox-
ylation of the cholesterol is produced, catalyzed by the enzyme cytochrome P450 
Figure 1. 
Bile acids: chemical structure.
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cholesterol 7a-hydroxylasa (CYP7A1). The BA synthesis can also occur through 
an “alternative” or “acidic” way, where the CYP27A1 intervenes and changes the 
BA oxysterols. Unlike the CYP7A1, the CYP27A1 is not regulated by the BA and is 
estimated only the 6% of the synthesis of BA is produced through this way. Before 
its secretion in the canalicular biliary light for the storage in the biliary gold bladder 
as mixed micelles with phospholipids and cholesterol, the primary BA are mainly 
conjugated with taurine and glycine, forming the conjugated BA, that with the Na+ 
and K+ form the biliary salts. When ingesting a food, the contraction of biliary gold 
bladder expels the micellar BA to the intestinal light to help digestion. In the gut, 
the intestinal bacteria deconjugate and dehydroxylate the primary BA, resulting in 
other species, denominated secondary BA: deoxycholic acid (DCA), a CA deriva-
tive, and ursodeoxycholic acid (UDCA), a CDCA derivative. The enterohepatic 
circulation allows the 95% of the BA to be reabsorbed from the distal ileum and 
transported back to the liver through portal circulation. Only 5% of the BA are not 
reabsorbed and are eliminated through feces. This small amount of loss is recovered 
through the novo synthesis of the BA in the liver. The size of the BA reserve is 
strictly regulated by the liver and gut to avoid a cytotoxic accumulation. When the 
reserve of BA increases, a feedback mechanism is activated, ruled by the interac-
tion of several nuclear receptors, mainly the farnesoid X nuclear receptor (FXR) 
to inhibit the novo synthesis of BA. Therefore, the FXR is a “BA sensor,” when the 
BA are joined to this receptor, they mediate their own synthesis control to provide a 
strict regulation of its reserve [13–15].
2.3 Bile acid therapy in hepatobiliary disease: role of UDCA
BA as therapeutic agent are appropriated in the chronic cholestasis deceases. BA 
can be orally administered following two strategies, the “displacement therapy” 
and/or “replacement therapy.” UDCA may be used to displace endogenous BA to 
decrease the intrahepatic concentration of potentially cytotoxic BA accumulated in 
cholestasis. On the other hand, primary BA such as cholic acid (CA) might be used 
to replace a depleted BA pool resulted from defective biosynthesis on consequence 
to restore the physiological function of BA [16, 17].
UDCA (3α-7β-hydroxy-5β-cholan-24-oic acid) is naturally occurring BA, 
that normally constitutes 1–2% of the BA in human bile. UDCA is obtained by 
7α-epimerization of the primary BA chenodeoxycholic acid (CDCA), by intestinal 
bacteria. [18] UDCA and CDCA differ in the hydroxyl group orientation at seventh 
position, allowing higher hydrophilicity of UDCA in comparison to CDCA.
UDCA is a weak acid (pKa = 5), and poorly water soluble, however, its solubility 
increases directly to the increase of the solution pH. After orally administrations, 
UDCA must be solubilized in mixed micelles present in small intestinal content 
in order to allow absorption [19, 20]. During the cholestasis disease, the UDCA 
bioavailability is limited due to the reduction of endogenous BA micelles in the duo-
denal lumen. Unconjugated UDCA is absorbed by passive diffusion in the proximal 
jejunum and in the ileum, thus extracted from portal venous blood by the liver and 
conjugated with glycine or taurine. Conjugated UDCA is secreted into the bile.
It is worth mentioning that in the UDCA oral administration, the half-life of the 
UDCA in the portal circulation is short, thus the maximum concentrations in liver/
bile achieved by dividing the dose equally over 24 h are adequate.
UDCA is the BA of choice in view of the proven efficacy and lack of side effects 
in the treatment of cholestasis diseases. In the case of CDCA, its inherent toxicity is 
related to the fact that CDCA undergoes bacterial conversion dihydroxylation to a 
toxic, monohydroxy BA, like lithocholic acid (LCA), unlike UDCA, which is more 
resistant to bacterial dihydroxylation [21, 22].
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The versatility presented by UDCA in the treatment of cholestatic diseases is due 
to its multiple action mechanisms:
• Biliary stones dilution
• Changes in the BA reserve hydrophobicity level
• Protection against the cellular death induced by cytotoxic BA
• Modulation of the expression of the transporters and the liver’s enzymatic 
systems
• Normalization of the altered cellular location of hepatocellular transporters
• Immunoregulatory effects
2.3.1 Biliary stones dissolution
UDCA reduces the content of cholesterol in the bile by reducing the hepatic syn-
thesis of cholesterol and its absorption by the gut itself. In addition to solubilizing 
the cholesterol into micelles, it causes the cholesterol to scatter into liquid crystals in 
an aqueous medium causing a favorable environment for the dissolution of biliary 
stones. In addition to this, reduces the viscosity and improves the bile flow.
2.3.2 Changes in the BA reserve levels of hydrophobicity
In the cholestasis, the increase of hydrophobic BA produces the cytolysis of plas-
matic membrane. In normal individuals, the UDCA represents not more than 4% of 
the complete endogenous BA reserve. Under a treatment with UDCA, this percent-
age increases to 40–60% under a conventional dosage of 13–15 mg/kg/day, becom-
ing the UDCA the predominant BA, which shifts the more hydrophobic endogenous 
BA. Therefore, the substitution of the potentially toxic hydrophobic endogenous 
BA in the total BA group to a hydrophilic turns the bile more hydrophilic and less 
cytotoxic, reducing the hepatic lesion.
2.4 UDCA and oxidative stress
It has been proposed that UDCA antioxidative action is due to the induction of glu-
tathione (GSH) synthesis and in this way, mitochondrial injury apoptosis is prevented 
[23]. UDCA activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway 
and induces the translocation of nuclear factor-E2-related factor 2 (Nrf2) into the 
nucleus. Hence, it could be hypothesized that UDCA increases the gene expression of 
enzymes associated with GSH synthesis and induces the down-regulation of intracel-
lular ROS levels [24]. In a similar fashion, insulin reduces oxidative stress by the activa-
tion of PI3K and extracellular signal-regulated protein kinase in HepG2 cells [25]. 
Therefore, both UDCA and insulin may exert a cytoprotective effects against oxidative 
stress and. Noteworthy, UDCA may reduce fatty acids-induced insulin resistance.
3.  Coenzyme Q10: generalities, clinical approaches and its relation to 
intrahepatic cholestasis of pregnancy
Coenzyme Q (CoQ ) is an endogenous lipophilic compound synthetized in 
all tissues and cells. The biosynthetic pathway of CoQ in eukaryotes has been 
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characterized by studies of mutants deficient in CoQ in Saccharomyces cerevisiae. 
The biosynthesis of CoQ initiates with the hydroxybenzoic acid to which a polyiso-
prenoid lipid tail is attached. Thus, CoQ is the product of two different converging 
biosynthetic pathways: the synthesis of 4-hydroxybenzoate, derived from the 
metabolism of tyrosine and the synthesis of the isoprene side chain that begins with 
the conversion of acetyl-coenzyme A (CoA) through the mevalonate route and 
regulated by the HMG CoA reductase. Formerly, the trans-prenyl transferase cata-
lyzes the condensation of farnesyl pyrophosphate with numerous trans isopentenyl 
pyrophosphates, to form the long isoprenoid chain. Finally, these two pathways 
converge in a terminal step, where 4-hydroxybenzoate and polyprenyl pyrophos-
phate are linked by a condensation reaction catalyzed by the enzyme polyprenyl 
4-hydroxybenzoate transferase [26].
Due to its ubiquitous distribution, CoQ is also called ubiquinone. In mammals, 
ubiquinone contains a 2,3-dimethoxy-5-methylbenzoquinone core with, pre-
dominantly, a hydrophobic 10 isoprenyl units, so it is designated as coenzyme Q10 
(CoQ10, Figure 2).
CoQ10, mainly placed in the inner mitochondrial membrane, plays its principal 
role in promoting the electron transfer from complexes I and II to complex III 
within the mitochondrial respiratory chain to finally obtain cellular energy [27]. 
Taking into account its redox properties, CoQ10 also acts as a potent lipophilic 
antioxidant, scavenging oxygen reactive species, protecting lipids, protein, and cel-
lular DNA and being involved in multiple steps of vital cellular metabolism such as 
the electron transfer in plasmatic membranes [28] and lysosomes [29], modulation 
of apoptosis [30, 31] and proton transport between uncoupled proteins [32]. CoQ10 
also has an important intracellular signaling role in modulating the mitochondrial 
permeability transition pore [33].
Although its biosynthesis is not completely dilucidated, it is well known that 
different mutations in some genes which codify for proteins within its biosynthetic 
pathway have been identified. These mutations define the primary CoQ10 deficien-
cies [34–40]. At this time, from the 13 known CoQ genes direct or indirect related 
to CoQ biosynthesis, it is recognize that eight of them can cause CoQ10 deficiency 
and disease [41]. Primary CoQ10 deficiencies are a group of rare diseases of clini-
cally heterogeneous appearance suggesting an autosomal recessive inheritance, 
because relatives are often affected, whereas parents are characteristically unaf-
fected. The four most frequent clinical phenotypes associated with primary CoQ10 
deficiencies are encephalomiophaty, cerebellar ataxia, multisystemic infantile form, 
and glomerulophaty and myophaty, all of them having a muscular and neurologic 
compromise [27]. Patients affected with primary CoQ10 deficiency, although its 
clinical severity, highly respond to CoQ10 supplementation being most effective the 
sooner the treatment begins [35, 42].
On the contrary, secondary CoQ10 deficiency is more frequent and of less severe 
clinical presentation. However, its treatment only ameliorates the symptoms although 
improve life quality. Secondary CoQ10 deficiency is associated to different patholo-
gies such as neuro-muscular degenerative pathologies, cardiovascular, thyroid 
Figure 2. 
Coenzyme Q10: (A) oxidized form and (B) reduced form.
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and reproductive diseases as well as cancer among others [43–46]. Coenzyme Q10 
deficiency is commonly found associated to mitochondrial oxidative phosphoryla-
tion impairment, probably as an adaptive mechanism to maintain a balance in 
mitochondrial redox status. However, in spite of the high incidence of secondary CoQ 
deficiencies, the precise mechanisms underlying these secondary deficiencies remain 
unidentified specially in non-mitochondrial oxidative phosphorylation disorders [47].
What is certain is that final cellular CoQ10 concentration is related to the bal-
ance existing between biosynthetic and dietary supply on one side and energetic 
consumption on the other [48].
In a previous work, we have demonstrated a reduced plasmatic level of CoQ10 in 
mothers with intrahepatic cholestasis of pregnancy (ICP) as well as in an animal 
model, being the first report connecting CoQ10 deficiency to this disorder [49]. 
Later, it was confirmed in another study, which analyzed fetal CoQ10 levels in cord 
blood from ICP mothers [50]. It is well known that ICP is a high-risk pregnancy dis-
ease characterized by the accumulation of total serum bile acids, with an enhanced 
proportion of the hydrophobic bile acids which are highly cytotoxic. During the 
last decade, it was found many evidences suggesting that hydrophobic bile acids 
increase is responsible for the higher oxidative stress observed in ICP [51–53]. Thus, 
it was reasonable to suspect that CoQ10 levels could be diminished, secondary to 
the oxidative stress and/or mediated by a metabolic feedback [50]. Furthermore, 
a depleted CoQ9 levels (the predominant form of ubiquinone in rodents) was also 
observed in plasma, brain and muscle in a cholestatic rat model together with a 
positive correlation between CoQ9 and ursodeoxycholic/lithocholic acid ratio 
(UDCA/LCA). The latter suggests that increased plasma LCA may be closely related 
to CoQ9 decrease in blood and tissues [49].
CoQ10 decrease in ICP possibly reveals a disturbance on the delicate bal-
ance between oxidative stress and antioxidant defenses, thus accumulating large 
amounts of free radicals, imparing energy production, and increasing risk for the 
fetus. Although the relationship between CoQ10 and serum bile acids is not well 
established, it is possible that reduced CoQ10 levels result from enhanced ubiqui-
none extraction from blood because of higher cellular demand. As it was previously 
mentioned, it is also probable that CoQ10 depletion may be caused by increased 
proportion of circulating and intracellular hydrophobic bile acids and enhanced 
consumption of the CoQ10 by free radicals and/or a metabolic down regulation. The 
relationship between CoQ and bile acids will be discussed in the next section.
Since CoQ10 is a potent antioxidant and is even proposed as the first line of 
defense against oxidative insult [54], its tissue distribution and plasma levels will be 
dependent on its susceptibility to the oxidative stress induced by cholestasis.
4. Bile acids and coenzyme Q10: possible relationship
Several studies have provided evidence that oxidative stress may play an impor-
tant role in the pathogenesis of hepatic injury in animal models of cholestasis  
[52, 55–58] and in humans [59–61].
Hepatic mitochondria have been proposed as the most important cellular source 
of reactive oxygen species (ROS) induced by bile acids (BA). Hydrophobic BA 
impair respiration and electron transport in hepatic mitochondria. Krähenbühl 
et al. reported that hydrophobic BA decrease the activities of several enzyme com-
plexes involved in the electron transport chain, such as complexes I, III, and IV but 
not affected complex II in isolated rat liver mitochondria. Furthermore, hydropho-
bic BA decrease the mitochondrial membrane potential developed upon succinate 
energization and decrease state three and enhance state four in mitochondria [62].
9Cholestasis: The Close Relationship between Bile Acids and Coenzyme Q10
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Yerushalmi et al. [63] proposed that ROS are generated at the ubiquinone-com-
plex III interaction of the respiratory chain in hepatic mitochondria upon exposure 
to BA. Additionally, Botla et al. [64] reported that hydrophobic BA initiates the 
membrane permeability transition in hepatic mitochondria. In this context, oxida-
tive stress results from an imbalance between increased free radical and impairment 
of antioxidant systems.
Therefore, the link between BA and CoQ has recently achieved clinical relevance 
and open to potential therapeutics challenges. As it was aforementioned, a study 
with a validated animal model of ICP, which shows similar biochemical hepatic 
alterations as observed in ICP patients, showed a significant decrease in CoQ9 
and α-tocopherol in plasma that correlated negatively with the increase in LCA 
levels in the animal model of ICP [49]. Stocker and Bowry reported that CoQ acts 
earlier than α-tocopherol in the antioxidant system, thus the reduction of plasmic 
CoQ could be considered as an early marker of oxidative insult [54]. The decrease 
in these antioxidants may contribute to increase oxidative stress in ICP [49]. CoQ 
plasmatic levels more likely reflect the degree of metabolic request; in this case 
decreased levels may be related to consumption by free radicals or by increasing 
cellular demand. On the other hand, tissue CoQ levels are related to the balance 
between biosynthesis, dietary supply and energetic consumption [48]. The increase 
in BA has different effect over CoQ tissue levels. It was observed that skeletal 
muscle and brain were more susceptible to oxidative stress and showed a decrease 
in CoQ levels in ICP animals, whereas liver and heart content of CoQ remained 
unchanged. An hepatic paradox described in animal model of cholestasis including 
EE cholestasis, where the activity of HMG-CoA reductase and 7 alpha hydroxylase 
is increased despite the increase of BA, could possible explain this finding [65–68]. 
Thus, taking into account, that CoQ is synthesized via HMG-CoA reductase, it is 
possible that levels were maintained by an increase in its synthesis [49].
In accordance with those results, a significant decrease in CoQ10 and vitamin 
E levels was also observed in ICP patients respect to control pregnancies, coupled 
to an increase in total serum BA with a more hydrophobic profile [49]. It is worth 
mentioning that neonates are highly susceptible to oxidative damage caused by 
ROS, since the extrauterine environment is richer in oxygen than the intrauterine 
environment [69]. This problem is further aggravated by the low efficiency of 
natural antioxidant systems in the neonate that could be worsened if the antioxi-
dant capacity of mother is deficient [48]. In addition, the direction of placental BA 
gradient, in normal pregnancy occurs from the fetus to the mother in order to pro-
mote toxic compounds elimination from the fetal compartment, while in ICP, this 
gradient is inverted allowing to accumulate BA in the fetal compartment [70, 71]. 
Thus, decreased CoQ10 levels in mothers with ICP may pose a risk for the newborn.
Recently, another study which evaluates umbilical cord blood of newborn from 
ICP mothers showed a decrease in cholesterol normalized CoQ10 content and an 
increase in total serum BA respect to normal pregnancy [50]. The results obtained 
by Martinefski et al. demonstrated a highly prooxidant environment.
Nowadays, since the relationship between CoQ and BA is not well established, 
two explanations have been hypothesized. On one hand, during ICP, cholesterol lev-
els could possibly be maintained due to a mevalonate pathway deviation flow that 
absorbs another branch of the metabolic flow including those required to support 
CoQ synthesis [72].
On the other hand, hydrophobic BA stimulate the generation of ROS leading 
to a consumption of different antioxidants, including CoQ. Both scenarios led to a 
secondary CoQ deficiency.
In the field of cholestasis therapeutics, CoQ10 synthetic analog (idebenone) has 
shown to prevent BA stimulation of ROS from hepatic mitochondria and isolated 
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hepatocytes [63]. Therefore, taking into account the deficiency of CoQ found in 
ICP, supplementation with CoQ10 could represent a new complementary therapeu-
tic proposal for ICP in order to protect both the mother and the newborn. However, 
further studies are required to obtain a deeper conclusion.
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